Medtronic's PAD tech beats angioplasty; Vital Therapies dials down its IPO plan;

@FierceMedDev: CyVek immunoassay technology gets $10M investment. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: After a successful IPO, LDR looks to raise more cash. News | Follow @VarunSaxena2

@EmilyWFierce: Motorized, sensor-driven wheelchair could provide a new level of mobility for those with severe disabilities. Article | Follow @EmilyWFierce

@MichaelGFierce: DNA nanorobot delivers drugs through flap that opens and closes. More from FierceDrugDelivery | Follow @MichaelGFierce

> Medtronic's ($MDT) IN.PACT Admiral drug-coated balloon beat out standard angioplasty in treating peripheral artery disease, the company said. News

> CardioKinetix's implanted ventricular device performed well in 12-month results, the company said, improving heart function, 6-minute walk test performance and rates of hospitalization. More

> Artificial liver outfit Vital Therapies has reduced its expected range in a second attempt at going public, eyeing $63 million at between $13 and $15 per share. Item

Biotech News

@FierceBiotech: Little Deciphera raises its cancer R&D flag in Boston's bustling biotech hub. More | Follow @FierceBiotech

@JohnCFierce: Agios shares spike on enthusiastic response to small, early-stage leukemia study. Story | Follow @JohnCFierce

@DamianFierce: Here's FierceBiotech's look at every drug developer IPO from the first quarter. Report | Follow @DamianFierce

@EmilyMFierce: 40% of the world's population is at risk from dengue. More in WHO's report for World Health Day. Report | Follow @EmilyMFierce

> Roche's pRED jumps into epigenetics with $521M-plus cancer drug deal. Article

> Sanofi decides to take a second shot on Lemtrada app. More

> Pfizer's flagship palbociclib stymies cancer progression but falls short on survival. News

Pharma News

@FiercePharma: Top-read story this weekend: Novartis fighting two-pronged legal battle in India on Galvus patent. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. Article | Follow @TracyStaton

@EricPFierce: Daiichi Sankyo hinted months ago it was tired of Ranbaxy's issues. Buyout means Sun Pharma takes them on. More | Follow @EricPFierce

@CarlyHFierce: Novartis meningitis B vaccine Bexsero receives FDA breakthrough therapy designation in the U.S. Release | Follow @CarlyHFierce

> GlaxoSmithKline confronts new bribery allegations, this time in Iraq. News

> Sanofi misled investors with rosy Lemtrada predictions, lawsuit alleges. More

> Mallinckrodt bets $5.6B on Questcor and its controversial Acthar drug. Story

CRO News

> Clinipace signs up to get a brain-stimulating device on the U.S. market. Article

> WuXi bets on anti-counterfeiting tech with an eye on drug safety. More

> Actavis picks Particle Sciences for generics development. Story

> AMRI expects its $41M Cedarburg deal to pay off right away. News

> Evotec lands two more deals to share risks and rewards of R&D. Report

> Charles River wraps up $179M deal for Galapagos' CRO biz. Item

Biotech IT News

> Merck KGaA and Pfizer tap into Broad Institute's data skills for lupus project. Story

> Tufts survey shows social media still on fringes of clinical trials. More

> Billionaire-backed startup puts Big Data, AI at the heart of drug discovery. News

> Merck vaccine plant taps R&D's Big Data platform to solve yield conundrum. Article

> IMS Health stock jumps after second biggest U.S. IPO of 2014. Item

> Europe to create public clinical trial results database after passing law. Report

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.